Home > Drug Discovery > COVID-19 R&D
COVID-19 R&D (COVID-19 R&D)

ProtTech has developed recombinant COVID-19 (SARS-COV-2) N Protein to be used for COVID-19 research and development.


SARS-CoV2 nucleocapsid protein (N protein) contains multiple T-cell and B-cell epitopes. We have developed an E. coli based expression system to express N protein at high yield with the native sequence, and have developed the procedure to purify the N-protein to a high purity.


Please click here if you would like more information about our recombinant SARS-CoV-2 N protein.


SARS-CoV-2 uses the SARS-CoV receptor ACE2 for entry and the serine protease TMPRSS2 for S protein priming. A TMPRSS2 monoclonal antibody might constitute a treatment option.

Please click here if you would like more information about our TMPRSS2 monoclonal antibody.